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Abstract
Purpose The grape and wine polyphenol resveratrol exerts
cardiovascular benefits but evidence from randomized hu-
man clinical trials is very limited. We investigated dose-
depending effects of a resveratrol-containing grape supple-
ment on stable patients with coronary artery disease (CAD)
treated according to currently accepted guidelines for sec-
ondary prevention of cardiovascular disease.
Methods In a triple-blind, randomized, placebo-controlled,
one-year follow-up, 3-arm pilot clinical trial, 75 stable-CAD
patients received 350 mg/day of placebo, resveratrol-
containing grape extract (grape phenolics plus 8 mg resvera-
trol) or conventional grape extract lacking resveratrol during
6 months, and a double dose for the following 6 months.
Changes in circulating inflammatory and fibrinolytic bio-
markers were analyzed. Moreover, the transcriptional profil-
ing of inflammatory genes in peripheral blood mononuclear
cells (PBMCs) was explored using microarrays and functional
gene expression analysis.
Results After 1 year, in contrast to the placebo and conven-
tional grape extract groups, the resveratrol-containing grape
extract group showed an increase of the anti-inflammatory
serum adiponectin (9.6 %, p00.01) and a decrease of the
thrombogenic plasminogen activator inhibitor type 1 (PAI-1)
(−18.6 %, p00.05). In addition, 6 key inflammation-related
transcription factors were predicted to be significantly activat-
ed or inhibited, with 27 extracellular-space acting genes in-
volved in inflammation, cell migration and T-cell interaction
signals presenting downregulation (p<0.05) in PBMCs. No
adverse effects were detected in relation to the study products.
Conclusions Chronic daily consumption of a resveratrol-
containing grape nutraceutical could exert cardiovascular
benefits in stable-CAD patients treated according to current
evidence-based standards, by increasing serum adiponectin,
preventing PAI-1 increase and inhibiting atherothrombotic
signals in PBMCs.
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Introduction
Patients with established coronary artery disease (CAD) are at
very high risk of recurrent cardiovascular events [1]. Athero-
thrombosis results from complex interactions between modified
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lipoproteins, monocyte-derived macrophages, components of
innate and adaptive immunity, and the normal cellular elements
of the arterial wall [2]. The activation of inflammatory pathways
in atherothrombosis is not confined to coronary lesions but
involves the participation of peripheral blood mononuclear cells
(PBMCs) that are important actors in atherosclerosis and in acute
manifestation of plaque destabilization [3]. In the whole process,
some nuclear receptors respond to oxidative stress and inflam-
matory stimuli by regulating the expression of genes involved in
inflammation and lipid metabolism [4]. Rising data suggest that
integrated research work, approaching different pathways, is
needed for better understanding the molecular basis of cardio-
vascular disease (CVD) [5].
Current guidelines in secondary prevention of CVD deal
not only with clinical areas of intervention but also with the
implementation of healthy lifestyles, including a healthy diet
[6]. Some specific foods such as olive oil, chocolate, walnuts
and red wine exert cardiovascular benefits due to the presence
of specific compounds such as omega-3-polyunsaturated fatty
acids [7] and polyphenols [8]. In this regard, the grape and
wine polyphenol resveratrol has shown cardiovascular bene-
fits through many animal studies [9–11]. However, the evi-
dence in humans is particularly limited [12].
Our aims were to investigate the effects of a 1 year
dietary intervention with a resveratrol-containing grape ex-
tract on the inflammatory and fibrinolytic status of stable
CAD patients and treated according to current guidelines. In
addition, we aimed to explore whether inflammatory path-
ways were affected in PBMCs from these patients in re-
sponse to the dietary intervention, through a microarray
approach focussed on several inflammation-related tran-
scription factors as potential regulation targets.
Methods
Patients and Study Design
Stable CAD patients, treated according to current accepted
guidelines for secondary prevention of CVD, were recruited
at the Morales Meseguer University Hospital (MMUH)
(Murcia, Spain). The study was included in the Spanish
National Research Project BFU2007-60576 and conformed
to the ethical guidelines of the 1975 Declaration of Helsinki
and its amendments. The design was approved by the Clin-
ical Ethics Committee from the MMUH (reference 02/07)
and by the CSIC’s Bioethics Committee (Madrid, Spain).
Inclusion and exclusion criteria are indicated in Fig. 1a. A
placebo-controlled, monocenter, triple-blind, dose–re-
sponse, 1-year follow-up, randomized 3-arm pilot trial was
conducted (Fig. 1b). Seventy-five out of 245 eligible
patients were randomly divided in 3 equal numbered groups
using a computer-generated random number sequence. The
groups were coded as A (placebo, maltodextrin), B (GE,
conventional grape extract) and C (GE-RES, resveratrol-
containing grape extract). The primary end point was the
change in high-sensitivity C-reactive protein (hsCRP) level
from baseline to 12 months. Sample size was calculated to
detect a difference of 1 mg/L on hsCRP, with a power of 80 %
and a 2-sided test with anα of 0.05. Secondary outcomeswere
plasminogen activator inhibitor type 1 (PAI-1), adiponectin,
interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis
factor alpha (TNFα), soluble CD40 ligand (sCD40L) and
soluble vascular adhesion molecule (sVCAM). Participants
were given detailed trial information and required to provide
written informed consent. The trial was registered at clinical-
trials.gov as NCT01449110.
Study Products and Intervention
Study products were provided to patients in identical code
labeled (A, B or C) capsules, containing 350 mg of either
maltodextrin (placebo), GE or GE-RES plus 20 mg of exci-
pients (magnesium stearate and SiO2) and packed in same-
code labeled blank boxes. The polyphenolic composition of
both GE and GE-RES was very similar as previously reported
[13] (~25 mg anthocyanins, ~1 mg flavonols, ~40 mg procya-
nidins, and ~0.8 mg hydroxycinnamic acids), but GE-RES
also contained 8.1±0.5 mg resveratrol per capsule. Resvera-
trol is a phytoalexin and its content is very low in grapes and
derived products. The GE-RES extract used in the present trial
was obtained from grapes following a patented procedure that
uses ultraviolet light to increase the resveratrol content [14].
These products (including GE-RES) were kindly provided by
Actafarma S.L. (Pozuelo de Alarcón, Madrid, Spain). Patients
were instructed to take 1 capsule/day in the morning for the
first 6 months and 2 capsules/day for the following 6 months
and to return the remaining capsules at trial conclusion. More-
over, participants were requested to keep their medication
(Table 1), customary lifestyle and diet throughout the trial
and to minimize the intake of grape-derived products, includ-
ing red wine. Dietary habit changes, treatment interruptions
and adverse effects (digestive discomforts, allergic reactions,
etc.) were monitored through questionnaires and phone calls
along the study. In addition, patients noted down their dietary
intake in the 3 days prior to blood withdrawal and were
instructed to fast overnight before blood collections.
Sampling Procedure
Blood samples were collected between 8 and 10 AM at
baseline, 6 and 12 months and the corresponding serum or
plasma samples were kept at −80 °C until analysis. Serum
levels of inflammation-related markers and PAI-1were mea-
sured, at least in duplicate, by enzyme-linked immunosorbent
assays (ELISA) as previously described [15]. Those
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determinations that yielded either borderline or statistically
significant changes were further repeated to confirm the
results.
Microarrays, Bioinformatic Tools and Functional Analysis
For the analysis of peripheral blood mononuclear cells
(PBMCs), a subpopulation of diabetic and hypertensive
male patients was selected from the total population of
participants. PMBCs were isolated from EDTA-treated
blood at baseline, 6 and 12 months and their RNA was
extracted [16]. Afterwards, 18 patients included in this
subpopulation were randomly chosen (6 from each group)
for microarray analysis. Microarrays (Affymetrix) were
performed on samples from individual patients (not pooled)
at baseline, 6 and 12 months for a total number of 54
microarray analyses. Differentially expressed genes were
analyzed and uploaded into Ingenuity Pathway Analysis
(IPA) software (Ingenuity® Systems, Redwood City, CA).
Significant changes were defined as those with an adjusted
p-value<0.05 (FDR, false discovery rate: 5 %) and with
ratios >1.2 (up-regulation) and<−1.2 (down-regulation).
Minimum Information About a Microarray Experiment
(MIAME) compliant data were submitted to the Gene
Expression Omnibus database (GEO; accession number
GSE36930). Detailed methodology regarding PBMCs iso-
lation, RNA extraction, microarray procedures and func-
tional analysis can be found in Supplementary Methods.
Excluded  (n=170)
-Not meeting inclusion criteria (n=147)
-Declined to participate (n=23)
Allocated and received  intervention 
(n = 25)
Follow-up (0-6months)
1 capsule/day (350 mg/day)
Allocated and received  intervention 
(n = 25)
Allocated and received  intervention 
(n = 25)
Enrollment
Screened for eligibility (n=245)
Randomized (n = 75)
Randomized allocation
Group A
(placebo)
Group B
(GE)
Group C
(GE-RES)
Lost to follow-up (n = 0)
Analyzed (n = 25)
Lost to follow-up (n = 0)
Analyzed (n = 25)
Lost to follow-up (n = 0)
Analyzed (n = 25)
Analysis: 6 months
Discontinued intervention (n = 0)
Analyzed (n = 25)
Discontinued intervention (n = 0)
Analyzed (n = 25)
Discontinued intervention (n = 0)
Analyzed (n = 25)
Analysis: 12 months
Completed trial (n = 25)
Follow-up (6-12 months)
2 capsules/day (700 mg/day)
Analysis: Baseline
Inclusion criteria
− Age between 18 and 80 years and,
− Stable angina or acute coronary syndrome at least 6 months before 
the inclusion in the study and,
− Left ventricular ejection fraction    45 % and,
− New York Heart Association (NYHA) functional class I-II and,
− Medical therapy according to European Society of Cardiology 
guidelines (ESC), for more than 3 months before inclusion.
Exclusion criteria
− Age below 18 or above 80 years or,
− Pregnancy or,
− Liver enzymes    3 over normal values or,
− Renal failure (creatinin > 1.5 mg/dl) or,
− Steroid or anticoagulant treatment or,
− Habitual intake of food supplements (herbal 
preparations, ‘antioxidant’ pills, etc.) or,
− Infectious disease or,
− Neoplastic disease or,
− Other known chronic pathology.
a
b
Completed trial (n = 25)Completed trial (n = 25)
Fig. 1 Design of the trial. (a)
Inclusion/Exclusion criteria. (b)
Flow of participants through the
trial. A, placebo group; B,
conventional grape extract
group (GE); C, resveratrol-
containing grape extract group
(GE-RES); RAS-blockers,
renin-angiotensin system
blockers; ESC, European Soci-
ety of Cardiology
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Statistical Analysis
All statistical analyses were performed with SPSS v. 19.0
(SPSS Inc, Chicago, USA). Quantitative data were
expressed as mean±SD and qualitative data were expressed
as proportions. Patient baseline characteristics were ana-
lyzed by Chi–square test or one-way analysis of variance
(ANOVA). Parameters with skewed distribution were loga-
rithm transformed for analysis. Intra and inter-group com-
parisons were made using one-way analysis of covariance
(ANCOVA) for repeated measurements followed by post-hoc
for multiple comparisons. The covariates used for adjustment
were age, gender, body mass index, arterial hypertension,
smoking, diabetes mellitus, diagnosed hypercholesterolemia,
antiplatelet medication, β-blockers, renin-angiontensin sys-
tem blockers, type of statin and dietary habits (including red
wine or grape-derived products). Accepted significance level
was p<0.05 with 95 % coefficient interval (CI). Borderline
statistical differences (p00.05) and tendencies (p>0.05–0.1)
were also acknowledged.
Results
Patients’ Characteristics, Serobiochemical Variables
and Trial Compliance
All patients completed the study and none experienced
adverse effects (intolerance, dyspepsia, allergic reactions,
etc.) regarding the intake of the supplied products during
the trial period. As expected, questionnaires indicated quite
uniform dietary habits in this cohort undergoing secondary
Table 1 Baseline characteristics
of patients (n075) with coronary
artery disease (CAD) and treated
according to currently accepted
guidelines for secondary pre-
vention of cardiovascular
disease
Values are expressed as mean±
SD. No significant (p<0.05)
baseline inter-group differences
were found. A placebo group, B
grape extract group (GE), C
resveratrol-containing grape ex-
tract group (GE-RES)
Groups
A B C
(n025) (n025) (n025)
Age, years 58±9 59±10 60±12
Men, n (%) 21 (84) 19 (76) 24 (96)
Body mass index, kg/m2 30.6±4.3 30.8±4.6 29.7±5.1
Systolic blood pressure, mmHg 125±18 124±18 126±16
Diastolic blood pressure, mmHg 72±11 73±10 71±9
Heart rate, beats/min 61±9 66±9 63±11
Left ventricular ejection fraction, % 54±5 55±5 54±4
Stable angina, n (%) 3 (12) 4 (16) 2 (8)
ST-segment elevation myocardial infarction, n (%) 7 (28) 10 (40) 10 (40)
non-ST-segment elevation acute coronary syndrome, n (%) 15 (60) 11 (44) 13 (52)
Myocardial revascularization, n (%) 19 (76) 21 (84) 21 (84)
Coronary stenting 14 (56) 17 (68) 19 (76)
Coronary artery bypass grafting 5 (20) 4 (16) 2 (8)
Ischemic ictus, n (%) 1 (4) 1 (4) 2 (8)
Intermittent claudication, n (%) 4 (16) 5 (20) 5 (20)
Family history of premature ischemic heart disease, n (%) 10 (40) 8 (32) 10 (40)
Diabetes mellitus, n (%) 14 (56) 17 (68) 14 (56)
Hypertension, n (%) 17 (68) 16 (64) 19 (76)
Active smokers, n (%) 11 (44) 6 (24) 4 (16)
Antiplatelet therapy, n (%) 25 (100) 25 (100) 25 (100)
Acetyl salicylic acid 12 (48) 13 (52) 13 (52)
Clopidogrel 3 (12) 3 (12) 1 (4)
Both 10 (40) 9 (36) 11 (44)
Statins, n (%) 25 (100) 25 (100) 25 (100)
Atorvastatin 16 (64) 16 (64) 17 (68)
Rosuvastatin 2 (8) 4 (16) 3 (12)
Pravastatin 3 (12) 2 (8) 1 (4)
Fluvastatin 4 (16) 3 (12) 4 (16)
β Blockers, n (%) 20 (80) 22 (88) 22 (88)
Renin-angiotensin system blockers, n (%) 22 (88) 22 (88) 24 (96)
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prevention of cardiovascular risk (results not shown).
Tables 1 and 2 show patients’ baseline characteristics and
laboratory values at the inclusion. No clinically relevant
changes were observed in the routine serobiochemical var-
iables analyzed after 12 months (Supplementary Table 1).
The atherogenic blood lipid load, measured as the non-high
density lipoprotein-cholesterol fraction (non-HDLc), de-
creased by 10.2 % in group B (p00.01) and by 13.4 % in
group C (p00.03) (Supplementary Table 1). No changes were
observed in routine hematological parameters (results not
shown). Patients from all groups consumed more than 95 %
of the expected capsules (compliance levels >95 %). Thirteen
cardiac events occurred in the follow-up, i.e. 5 (3 acute coro-
nary syndromes-ACS, 1 elective coronary revascularization-
ECR, 1 stroke), 6 (3 ACS, 2 ECR, 1 stroke) and 2 ACS in
groups A, B and C, respectively. These patients continued
taking the capsules. All events occurred at least 2 months prior
to blood collections and resultant biomarker alterations were
expected to be stabilized by then. There were no fatalities
during the one-year follow-up.
Effect of Dietary Interventions on Inflammatory
and Fibrinolytic Markers
Figure 2 shows the overall impact of each dietary intervention
on circulating biomarkers after 6 and 12 months with respect
to their baseline values. In the placebo group (A), the anti-
inflammatory interleukin-10 (IL-10) and adiponectin signifi-
cantly decreased by 6.6 % (95 % CI −3.7 to −0.2, p00.03),
and 12.7 % (95 % CI −2.4 to 0.3, p00.01), respectively,
Table 2 PAI-1, inflammatory
markers and serobiochemical
variables of patients with coro-
nary artery disease (n075) in
secondary prevention of cardio-
vascular disease at the inclusion
Values are expressed as mean±
SD. A placebo group, B grape
extract group (GE); C
resveratrol-containing grape ex-
tract group (GE-RES). No inter-
group differences (p<0.05) were
found at baseline
Groups
A B C
(n025) (n025) (n025)
Plasminogen activator inhibitor type, ng/mL 18.7±14.4 19.8±14.9 17.2±10.3
High-sensitivity C-reactive protein, mg/L 3.3±2.2 3.5±2.3 3.9±4.1
Adiponectin, μg/mL 11.0±5.8 11.2±4.5 12.4±5.6
Tumor necrosis factor-α, pg/mL 13.7±8.6 14.2±8.7 14.9±8.6
Interleukin-6, pg/mL 2.6±1.7 2.2±1.7 2.3±1.8
Interleukin-10, pg/mL 19.6±12.4 22.7±16.1 23.05±16.7
Interleukin-6/Interleukin-10 0.16±0.14 0.12±0.12 0.12±0.1
Soluble CD40 ligand, ng/mL 7.5±3.9 6.5±4.4 6.1±3.6
Soluble vascular adhesion molecule type 1, ng/mL 1063±253 1033±368 1030±463
Total cholesterol, mg/dL 162.4±36.5 156.7±30.9 165.6±35.2
Low-density lipoprotein cholesterol, mg/dL 89.1±30.7 81.4±26.4 92.4±31.5
High-density lipoprotein cholesterol, mg/dL 39.5±8.7 43.2±10.2 44.8±7.2
LDLc/HDLc, mg/dL 2.3±0.2 1.9±0.2 2.0±0.1
non-HDLc, mg/dL 140±10 127±7 135±11
Triglycerides, mg/dL 139±61 138±49 123±48
Fibrinogen, g/L 3.3±0.5 3.6±0.5 3.5±0.5
D-Dimer, mg/L 0.13±0.07 0.12±0.06 0.13±0.05
Aspartate transaminase, U/L 24±10 24±6 30±11
Alanine transaminase, U/L 27±15 33±17 33±17
Alkaline phosphatase, U/L 184±60 190±57 180±45
Creatine phosphokinase, U/L 112±69 114±52 154±67
γ-Glutamyl transferase, U/L 39±21 40±27 34±17
Lactate dehydrogenase, U/L 305±46 317±59 361±72
Glucose, mg/dL 121±51 122±20 127±45
Glycated hemoglobin, % 6.3±1.3 6.4±0.4 6.6±1.3
Tyroid stimulating hormone, mU/L 2.4±1.2 1.7±0.8 1.7±1.2
Thyroxine, ng/dL 1.3±0.2 1.3±0.2 1.2±0.2
Bilirubin, mg/dL 0.6±0.3 0.5±0.2 0.6±0.2
Creatinin, mg/dL 1.0±0.3 1.0±0.3 0.9±0.2
Urate, mg/dL 6.5±1.6 6.2±1.5 5.8±1.5
Albumin, g/L 45.2±2.4 44.4±2.6 44.6±2.1
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whereas PAI-1 significantly increased by 38.5 % (95 % CI 3.5
to 10.9, p00.00) after 12 months (Table 3, Fig. 2). In group B
(GE, conventional grape extract) no marker was significantly
affected (Table 3, Fig. 2). In group C (GE-RES, resveratrol-
containing grape extract) a non-statistically significant dose-
dependent decrease of 8 % (p00.09) and 18 % (p00.17) was
observed for high-sensitivity C-reactive protein (hsCRP) after 6
and 12 months, respectively. Even though hsCRP decreased
38 % versus placebo after 12 months, no significant inter-group
differences were found (Table 3, Fig. 3). However, serum adipo-
nectin increased in this group (10 %; 1.2 μg/mL, 95 % CI 0.2 to
2.3, p00.01), with 80 % of patients showing a rise in this
marker’s level (Fig. 3). Interestingly, adiponectin values were
higher (23 %) in the GE-RES group than in placebo after
12 months (p<0.05) (Table 3, Figs. 2 and 3). A statistically
significant decrease (p<0.05) of adiponectin was seen after
12 months for the diabetic subgroup (n012) of placebo group.
Inversely to adiponectin, glycated haemoglobin levels presented
a significant increase for the same subgroup of patients at this
time point which was also correlated with a significant increase
of glucose levels (results not shown). An inverse correlation was
found between adiponectin vs. HbAc1 and adiponectin vs. glu-
cose levels although statistical significance was not reached
probably due to the small sample size.
Regarding PAI-1, a clear decrease was observed in the GE-
RES group after 12 months (−18.6 %, p00.05) (Table 3,
Fig. 2). Significant inter-group differences were observed
between groups A and C at 6 and 12 months, as well as
between groups A and B after 12 months (Table 3, Fig. 2).
In addition, even though statistical significance was not
reached, Fig. 2 shows clear inter-group differences for tumor
necrosis factor alpha (TNFα) and IL-6/IL-10 after 12 months.
GE-RES Downregulates Pro-Inflammatory Gene Expression
in PBMCs
Differentially expressed genes in PBMCs (at 6 and 12 months
vs. baseline; p<0.05) were analyzed for placebo, GE and GE-
RES groups. After 12 months, 6 key inflammation-related
transcription factors (TFs) were predicted to be significantly
activated or inhibited only in the GE-RES group (Table 4):
Kruppel-like factor 2 (KLF2), nuclear factor kappa-B (NF-
κB), activator protein 1 (Ap-1), proto-oncogen c-JUN (JUN),
activating transcription factor 2 (ATF-2) and CREB-binding
protein (CREBBP). According to the functions of these tran-
scription factors (Table 4), these results suggest a general
inhibition of the lymphocytes/monocytes-mediated inflamma-
tory response following the consumption of GE-RES. This
specific subset of transcription factors together with their
target genes were used to create a pathway using the Ingenuity
Pathway Analysis (IPA) software (Fig. 4). Accordingly, this
pathway called attention to a significantly downregulated
subset of 27 extracellular-space acting genes in group C
(GE-RES, Supplementary Table 2). Functional analysis
revealed their involvement in processes such as cell move-
ment, immune cell trafficking, cellular growth and prolifera-
tion, cell-to-cell signaling and interaction and inflammatory
response. Supplementary Table 3 includes a detailed list of
these genes and their functions.
Discussion
Resveratrol content in red wine has been recurrently used to
justify red wine benefits, such as the so-called ‘French
Paradox’, i.e. low mortality due to CVD in France compared
to that in other developed countries in spite of sharing CVD
risk factors such as obesity, fat intake, smoking, etc. [17].
However, the presence of resveratrol in the diet is almost
negligible [18] because it is a minor polyphenol whose
content in red wine is low and highly variable [19]. Resver-
atrol is a defensive compound (phytoalexin) that is synthe-
sized by grapes to face adverse environmental conditions
[14] and, by definition, its presence in grapes (and red wine)
is low and unpredictable. The vast majority of studies car-
ried out with resveratrol have used the synthetic molecule or
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Fig. 2 Changes of plasminogen activator inhibitor type 1 (PAI-1) and
inflammatory-related markers from baseline after 6 and 12 months.
Patients consumed 1 capsule/day for the first 6 months (350 mg/day)
and 2 capsules/day (700 mg/day) for the following 6 months. Percent
changes are expressed as mean±SD. Intra-group changes over time: *p
<0.05; #p00.05. Differences versus group A (placebo): ap<0.05
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non-dietary herbal preparations. Therefore, i) the consumption
of wine does not ensure the intake of enough resveratrol to
exert beneficial effects, ii) the conjecture that directly correlates
the cardiovascular protection of red wine and its resver-
atrol content is not fully true and iii) the specific con-
tribution of the minor resveratrol content against the rest
Table 3 Plasminogen activator inhibitor type 1 and inflammatory markers of patients with coronary heart disease (n075) after consumption of
placebo (group A, n025), grape extract (GE, group B, n025) or resveratrol-containing grape extract (GE-RES, group C, n025) for 12 months
Experimental values after 6 months Experimental values after 12 months
A B C A B C
High-sensitivity C-reactive
protein, mg/L
3.5±2.1 3.2±1.6 3.6±3.7 4.0±1.8 3.6±2.2 3.2±2.1
p-value 0–6 months 0.21 0.67 0.09‡, ↓8 %
p-value 6–12 months 0.13 0.56 0.40
p-value 0–12 months 0.66 0.95 0.17
Tumor necrosis factor-α,
pg/mL
14.5±9.2 14.4±8.6 14.4±8.6 15.2±7.0 14.7±9.9 13.8±8.2
p-value 0–6 months 0.63 0.93 0.56
p-value 6–12 months 0.38 0.75 0.30
p-value 0–12 months 0.49 0.76 0.15
Adiponectin, μg/mL 11.4±6.8 12.0±5.2 13.3±5.6 9.6±4.4 11.6±4.8 13.6±5.2
p-value 0–6 months 0.55 0.25 0.06‡, ↑7%
p-value 6–12 months 0.00*, ↓16 % 0.13 0.03*, ↑2%
p-value 0–12 months 0.01*, ↓13 % 0.48 0.01*, ↑10%
Interleukin-6, pg/mL 2.6±1.8 2.2±1.6 2.1±1.7 2.6±1.8 2.1±1.6 2.1±1.7
p-value 0–6 months 0.99 0.24 0.83
p-value 6–12 months 0.56 0.51 0.88
p-value 0–12 months 0.80 0.10‡, ↓5 % 0.84
Interleukin-10, pg/mL 18.6±13.3 22.2±17.2 23.6±17.0 18.3±12.2 21.8±16.9 23.3±16.9
p-value 0–6 months 0.01*, ↓5 % 0.40 0.42
p-value 6–12 months 0.55 0.33 0.93
p-value 0–12 months 0.03*, ↓7 % 0.14 0.45
Interleukin-6/Interleukin-10 0.15±0.12 0.13±0.11 0.11±0.10 0.17±0.14 0.13±0.11 0.11±0.10
p-value 0–6 months 0.64 0.24 0.24
p-value 6–12 months 0.10‡, ↑13% 0.50 0.66
p-value 0–12 months 0.19 0.48 0.27
Soluble CD40 ligand, ng/mL 8.1±3.4 6.5±3.8 6.5±2.8 7.5±2.5 6.4±3.3 6.2±2.1
p-value 0–6 months 0.54 0.97 0.61
p-value 6–12 months 0.18 0.69 0.55
p-value 0–12 months 0.30 0.78 0.83
Soluble adhesion vascular
molecule type 1, ng/mL
1101±251 1039±330 1071±561 1111±347 1087±332 996±443
p-value 0–6 months 0.07‡, ↑4% 0.91 0.36
p-value 6–12 months 0.82 0.31 0.09‡, ↓7 %
p-value 0–12 months 0.28 0.39 0.26
Plasminogen activator
inhibitor type 1, ng/mL
23.5±15.5 18.1±10.2 13.6±7.2 25.9±15.0 18.6±9.5 14.0±7.0
p-value 0–6 months 0.02*, ↑26% 0.55 0.05†, ↓21 %
p-value 6–12 months 0.26 0.52 0.50
p-value 0–12 months 0.00*, ↑38% 0.62 0.05†, ↓19 %
Values are expressed as mean±SD. Daily doses were 1 capsule (350 mg) from 0 to 6 months and 2 capsules (700 mg) from 6 to 12 months. A
placebo group, B grape extract group (GE), C resveratrol-containing grape extract group (GE-RES). *p<0.05; † p00.05. Tendencies (‡ p>0.05–0.1)
are also indicated. Inter-group differences (p<0.05) were found in adiponectin after 12 months (A vs. C); and in plasminogen activator inhibitor
type 1 after 6 (A vs. C) and 12 months (A vs. B; A vs. C)
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of major phenolic compounds in red wine is not known.
In this regard, we used a resveratrol-rich grape extract
(GE-RES) obtained from ultraviolet-treated grapes that
induced resveratrol to face such challenge. Therefore,
this nutraceutical offers the possibility of including
resveratrol in the human diet within its natural edible
matrix, the grape. In addition, in order to evaluate the
relevance of RES against the rest of the grape phenolics
we included a conventional grape extract (GE) group
(same grapes without UV treatment).
Adiponectin is an anti-inflammatory cytokine involved in
the pathogenesis of vulnerability of coronary lesions by
exerting protective pleiotropic effects on the vascular sys-
tem [20]. Adiponectin release has been reported to be sup-
pressed in the epicardial adipose tissue of patients with
obesity and coronary artery disease (CAD) [21]. Despite
its anti-inflammatory and protective role against cardiovas-
cular disease (CVD), high adiponectin levels have been
correlated with mortality in specific clinical conditions of
CAD patients [22]. However, in this case, it has been
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Table 4 Predicted activation status of inflammation-related transcription factors of differentially expressed genes in peripheral blood mononuclear
cells (PBMCs) from patient with coronary artery disease (CAD) after consumption of resveratrol-rich grape extract (GE-RES) for 12 months
Transcription
factor
Function Predicted
status
z-score References
Kruppel-like factor 2
(KLF2)
Negative regulator of pro-inflammatory monocyte activation. Its effect is
mediated through inhibition of nuclear factor-KB (NF-κB) and activator
protein 1 (AP-1) pathways. Activation of KLF2 strongly induces
thrombomodulin and endothelial nitric oxide synthase expression and
reduces plasminogen activator inhibitor type 1 (PAI-1) expression.
Activated 2.546 4
Activator protein 1
(Ap-1)
Together with NF-κB is one major inflammation regulator. NF-κB and AP-1
coordinated actions propagate inflammation via promoting transcription
of cytokines, chemokines, and other proinflammatory genes.
Inhibited 3.423 40
Proto-oncogen c-JUN
(JUN)
Major component of the heterodimeric transcription factor AP-1; plays an
important role in regulating cell growth, apoptosis, differentiation, and
transformation.
Inhibited 2.702 40
Activating transcription
factor 2 (ATF-2)
Component of the heterodimeric of AP-1; regulates the transcription of
genes involved in in the stress response, cell growth and differentiation,
and immune response.
Inhibited 2.661 40
CREB-binding protein
(cAMP response
element-binding)
Essential co-activator for nuclear receptors and several other classes of
regulated transcription factors like NF-κB and AP-1.
Inhibited 2.334 41
According to the Ingenuity Transcription Regulator Analysis (TRA). TRA examines the known targets of each transcription factor in the user’s
dataset and compares their expression in the experimental samples relative to control to what is expected from the literature. TRA defines a quantity
(z-score) that determines whether an upstream transcription factor has significantly more activated predictions than inhibited predictions (z>0) or
vice versa (z<0), where significance means that the observed number of activated or inhibited predictions are unlikely relative to randomly chosen
predictions (null hypothesis). In practice, the predicted activation status is only established when z-score >2 or<−2
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suggested that higher adiponectin levels are a consequence
rather than a cause, i.e. the attempt to protect, reduce or limit
endothelial damage provoked by an inflammatory milieu in
these patients [23, 24]. In fact, serum adiponectin values
have been reported to be lower in CAD patients with vul-
nerable plaques [25], acute myocardial infarct (AMI) and
unstable angina than in those patients with stable angina
[26]. In this regard, methods for increasing adiponectin have
been suggested as a promising therapy for the prevention
and treatment of CAD [27]. Unlike adiponectin, PAI-1 is
higher in CAD patients [28] and its reduction can decrease
CVD risk because the impairment of fibrinolysis, due to
high circulating PAI-1 levels, is associated with the devel-
opment of AMI [29]. The inverse relation between adipo-
nectin and PAI-1 has also been described in obese [30] and
stable angina patients [31]. However, the evolution of these
markers is not routinely assayed in the follow-up of CAD
patients with optimized medication [32, 33]. In fact, in the
present trial, even though patients were being treated
according to current evidence-based standards (Table 1),
both adiponectin and PAI-1 presented an unfavorable
evolution along the trial in the placebo group. Remark-
ably, the outcomes of our study suggest that a daily,
yearlong, dietary intervention with a resveratrol-rich
grape nutraceutical increases adiponectin and decreases
PAI-1 circulating levels in CAD patients, which is in
accordance with the effects exerted by resveratrol in a
number of in vitro and animal studies [34]. Other mech-
anisms related to the cardiovascular protection exerted by
resveratrol include the decrease in endothelin-1, adhesion
molecules to endothelium, platelet aggregation, and pro-
inflammatory cytokines, the increase of NO synthesis and
the activation of sirtuins, among others [35].
The specific mechanisms of action reported for GE-RES
have been linked to the regulation of genes involved in lipid
metabolism and metabolic disorders [36] and a reduction of
vascular oxidative stress resulting in the prevention of early
atherosclerotic lesions in the aorta of pigs fed with an
Fig. 4 Predicted pathways by
the Ingenuity Pathway Analysis
software (IPA) according to
microarrays results in peripher-
al blood mononuclear cells
(PBMCs). Green and red colors
designate down- and upregula-
tion of gene expression, re-
spectively. Transcription factors
involved in the predicted path-
way are listed in Table 4. Ex-
pression changes in
extracellular-space genes and
their functions are listed in
Supplementary Tables 2 and 3,
respectively
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atherogenic diet [15]. However, despite the abundant preclini-
cal cardiovascular benefits described for resveratrol [35], hu-
man clinical trials, especially long-term interventions, are very
scarce [11]. Resveratrol consumption has been reported to
improve glycemic control in diabetics [37, 38] and endothelial
function in CAD patients [39]. However, these studies in-
volved a short follow-up (maximum 3 months) and the statis-
tical analyses did not take into account possible covariates
(medication, age, gender, etc.) that could influence the results.
Recently, we have shown that a 6-months consumption of GE-
RES decreased the concentration of oxidized low-density
lipoprotein particles and apolipoprotein B in statin-treated
subjects at high CVD risk (primary prevention of CVD)
[13]. In the same cohort of subjects, we further reported the
improvement of their inflammatory (mainly by decreasing
hsCRP) and fibrinolytic (PAI-1) status after one year follow-
up [14]. In the present trial, CAD patients were treated with
higher statin doses than high-risk subjects in primary preven-
tion (i.e. 20 mg rosuvastatin, 40–80 mg atorvastatin, 40 mg
pravastatin or 80 mg fluvastatin). It is known that treatments
with high statin doses are correlated with a reduction of CRP
[40]. For example, 40 mg pravastatin decreased hsCRP by
13 % (median from 2.7 to 2.4 mg/L) [41] and 18 % (mean
from 3.6 to 3.1 mg/L) [42] after 6 months and 5 years, respec-
tively, in secondary prevention cohorts. Therefore, the high
statin dose could be behind the low added-effect on hsCRP
after consuming GE-RES in this study in comparison with our
previous trial in primary prevention of CVD [14]. Neverthe-
less, the evolution of hsCRP levels in the present trial was
clearly better in the GE-RES group than in the other groups
(Fig. 2). In contrast to the moderate effect on hsCRP, the
effects on PAI-1 and adiponectin upon consumption of GE-
RES were clearer in CAD patients than in primary prevention
of CVD [14].
Many of the reported effects for adiponectin are related to
the inhibition of pro-inflammatory signaling in PBMCs,
monocyte adhesion to vascular endothelium and migration
into tunica intima, macrophage activation and transformation
to foam cell, smooth muscle cell proliferation and migration
into the intima [25, 26]. Therefore, we next investigated,
through a microarray analysis, whether this dietary interven-
tion could affect inflammatory pathways in PBMCs. Gene
expression response to inflammatory signals is mediated
through the activation of transcription factors like NF-κB,
which contributes to the pathophysiology of inflammatory
disease and triggers monocyte recruitment into subendothelial
space, a crucial milestone in the pathogenesis of atherosclero-
sis [43]. Another important transcription factor is AP-1, whose
dimers such as JUN/ATF2 are involved in the regulation of
diverse subsets of target genes whose products regulate the
activation, proliferation, differentiation and apoptosis of leu-
kocytes [44]. In addition, the activity of both NF-κB and AP-1
is regulated by CREBBP [45]. All these transcription factors
were predicted to be inhibited following the yearlong con-
sumption of resveratrol-rich grape extract (GE-RES). Further-
more, KLF2, which downregulates PAI-1 expression and
negatively regulates pro-inflammatory activation of mono-
cytes through inhibition of NF-κB and AP-1 [4], was pre-
dicted to be activated exclusively in the GE-RES group. After
combining all the above transcription factors in a joint path-
way, a subset of 27 significantly downregulated genes, whose
products act in the extracellular space, stood out. The func-
tional analysis of this orchestrated downregulation pointed
towards the inhibition of clinically relevant key features in
atherothrombosis such as inflammation, cell migration and T-
cell interaction [5]. In this regard, Karastergiou et al. [17]
reported that the adhesion of monocytes to human endothelial
cells was increased by the release of epicardial adipose tissue
cytokines in CAD patients. Interestingly, adiponectin reversed
these atherogenic effects and this supports the link found in
our trial between adiponectin increase and the inhibition of
atherothrombotic signals in PBMCs from CAD patients be-
longing to the GE-RES group.
We next tried to correlate the effects of GE-RES with
circulating resveratrol and/or other phenolic metabolites
derived from the grape extract GE-RES. Plasma samples
were routinely analyzed using state-of-the-art analytical
techniques (UPLC-QqQ). However, we were not able to
detect circulating resveratrol or other grape-derived metab-
olites in the GE-RES group. This was in accordance with
our previous studies in both humans [13, 15] and pigs [16]
using the same grape nutraceutical. At first, this could be
explained by the low resveratrol dose assayed (8 mg for
6 months and 16 mg for the last 6 months), by the fast
clearance of resveratrol and also because blood withdrawals
were carried out after fasting overnight. In this regard,
Azorín-Ortuño et al. [46] coined the expression ‘Resveratrol
Paradox’ to illustrate the high activity exerted by resveratrol
despite its low bioavailability. Circulating resveratrol metab-
olites were not found in pigs fed with this nutraceutical as
stated above. However, a number of resveratrol metabolites
were detected in the aortic tissue of these pigs [16]. Al-
though the direct association between resveratrol and/or
specific circulating resveratrol metabolites and the biologi-
cal activity of resveratrol is far from being demonstrated in
vivo, this suggests that repetitive, chronic exposure of low
resveratrol doses such as those assayed in the present trial
could be directly related to the beneficial effects observed.
Overall, this implies that each specific product containing
resveratrol should demonstrate both its safety and efficacy.
Limitations
This is the longest exploratory trial dealing with resveratrol in
patients with CAD reported so far although we acknowledge
that the small sample size (n075) and follow-up (1 year)
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impede definite conclusions on the clinical impact of these
dietary interventions. There were 13 events during this trial,
i.e. acute coronary syndrome (ACS) cases such as unstable
angina, non-ST elevation myocardial infarction (NSTEMI)
and stroke/transient ischemic attack were all included as
events (there were no cases of STEMI or death). Overall, there
was a 16 % rate of events during the trial in these very high
risk patients. Data from stable patients undergoing secondary
prevention is scarce, nevertheless, our rate of events is very
similar to the one described in other observational reports such
as the REACH registry [47], where a population with a similar
profile to ours presented a 15.4 % rate of events in the first
year of follow-up. Regarding Spanish registries, similar pop-
ulations presented a rate of events between 14 and 44 % after
3 years of follow-up according to the cardiovascular risk
factors [48]. Other registries like the CLARIFY registry [49]
showed a year rate of events inferior to ours (around 7 %),
however, stroke was not included in the rate calculations
reported. In the present trial, in contrast to the 5 and 6 cardiac
events occurred in the placebo and GE groups, respectively,
only 2 ACS were recorded in the GE-RES group. However, a
larger sample size and longer follow-up is needed to confirm
this positive result. In addition, our microarrays results pro-
vide preliminary evidence regarding the possible role of the
genes and pathways studied in this trial. However, our patient
cohort was well characterized and the adjusted statistical
analysis as well as the long-term follow up supports that this
resveratrol-rich grape nutraceutical (GE-RES) could comple-
ment the optimized medication of these CAD patients. In our
opinion, the combined evaluation of circulating markers relat-
ed to cardiovascular disease risk and the gene expression
profiling of PBMCs yields an attractive translational approach
of molecular mechanisms to clinical applications in patients
with CAD.
Conclusion
In stable CAD-patients, the daily consumption of this
resveratrol-containing grape nutraceutical (GE-RES) for
1 year increased serum adiponectin, prevented plasminogen
activator inhibitor type 1 increase and inhibited athero-
thrombotic signals in PBMCs from these patients. The pres-
ence of resveratrol in the grape nutraceutical appeared
essential to exert these effects. Our data warrant further
research on this nutraceutical as a possible safe coadjuvant
food supplement in the follow-up of CAD patients.
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